Aptevo Therapeutics Inc. (APVO)

1.2501 +0.2901 (+30.22%) As of 09:44AM EDT. Market open.

Aptevo Therapeutics Inc.

2401 4th Avenue
Suite 1050
Seattle, WA 98121
United States
206 838 0500
https://www.aptevotherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 40

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Marvin L. White	President, CEO & Director	841.39k	N/A	1962
Mr. Jeffrey G. Lamothe CA	Executive VP & COO	722.51k	N/A	1966
Ms. SoYoung Kwon J.D., LL.M.	Senior VP, General Counsel, Business Development & Corporate Affairs	639.37k	N/A	1969
Ms. Daphne L. Taylor	Senior VP & CFO	N/A	N/A	1966
Dr. Dirk Huebner M.D.	Chief Medical Officer	N/A	N/A	1964

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Corporate governance

Aptevo Therapeutics Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.